$10.510
-0.040 (-0.38%)收盤時
價格預測
在 App 中開啟以解鎖更長週期的預測。
SGHC 相似圖表分析預測
Alphio's SGHC stock price prediction model matches the current SGHC Ltd tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $10.47 (-0.39%). The 1-week path is $10.17 (-3.26%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
該買進 SGHC Ltd 股票嗎?
SGHC Ltd appears to be a good buy right now due to its current price of $10.85, which is significantly below the analyst price target of $19 to $20. Additionally, the forward P/E ratio of 12.41 suggests the stock is undervalued compared to its earnings potential. The recent revenue growth of 18% year-over-year, reaching $684 million, highlights strong operational performance. However, a risk to consider is the recent 5-day change of -2.16%, indicating some short-term volatility.
SGHC 股價於 Wednesday 收在 $10.51,此前下跌 -0.38%
SGHC Ltd (SGHC) last closed at $10.5100002, losing -0.38%. These facts feed the 1-day and 1-week SGHC price prediction above.
預測驅動因素
SGHC Ltd(SGHC)的預測驅動因素綜合了相似的圖表形態、季節性與移動平均線。
Similar patterns
Bullish
Seasonality
Bullish
SMA 20
Bearish
SMA 200
Bearish
相似圖表形態
近期走勢與 SGHC 最接近的股票,依相似度排序。
SGHC 季節性分析
Historically the probability of a positive October return for SGHC is 69.70%. May offers the highest probability of a positive month at 100.00%, while January is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
SGHC 十年價格預測
| 月份 | 最低價 | 平均價 | 最高價 | 潛在報酬率 |
|---|---|---|---|---|
| Oct 2026 | $8.33 | $9.98 | $10.15 | -5.06% |
| Nov 2026 | $11.52 | $12.82 | $13.91 | +21.96% |
| Dec 2026 | $9.08 | $10.94 | $11.50 | +4.08% |
2026 年,SGHC Ltd(SGHC)預計區間為 $8.33 至 $13.91。
SGHC Ltd 2026 年月度預測
2026 年 Oct,SGHC Ltd 預計均價 $9.98,最低 $8.33,最高 $10.15。
2026 年 Nov,SGHC Ltd 預計均價 $12.82,最低 $11.52,最高 $13.91。
2026 年 Dec,SGHC Ltd 預計均價 $10.94,最低 $9.08,最高 $11.50。
本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。